Concerns & Risks -- 8/10

Favorable risk profile. Forward valuation below the med-tech peer set. Zero/negligible China exposure (US/international diabetes care). Dense near-term catalyst calendar (T2 non-insulin coverage expansion, CMS decisions, Stelo OTC ramp, G7 15-day, international expansion). Low regulatory risk (FDA-cleared, CMS coverage expanding). Held from 9-10 only by Abbott competitive pressure and the new-CEO execution question. Weight: 15%

Forward Valuation

Below Peer Avg

Discounted

China Exposure

~0%

US/international diabetes -- Non-issue

Dense Catalyst Slate

T2, CMS, Stelo, G7

Near-term

Abbott Competitive Pressure

FreeStyle Libre

Key watch item

Catalyst calendar

#	Catalyst	Detail	Impact
1	T2 Non-Insulin Coverage Expansion	Largest addressable population segment. CMS proposal and commercial payer follow-on would meaningfully expand TAM beyond current insulin-dependent base.	HIGH
2	CMS Coverage Decisions	Potential volume catalyst. Expanding Medicare coverage for CGM is a net positive for DXCM -- reimbursement is the enabler, not the headwind.	HIGH
3	Stelo OTC Ramp	First OTC CGM on the market. Validates consumer/wellness CGM category. International launch planned. Early contribution but validates long-term secular growth thesis.	HIGH
4	G7 15-Day Sensor	Reduces cost-per-day, improves patient compliance. Each 10-day to 15-day conversion cuts COGS ~33% per sensor. Structural margin improvement lever.	HIGH
5	International Expansion	Underpenetrated markets with growing diabetes prevalence. 15-day sensor economics unlock lower-reimbursement geographies. International revenue trajectory accelerating.	MEDIUM
6	GLP-1 Monitoring Integration	Emerging data suggests GLP-1 users wear CGMs more, not less. CGM at ~$1K/yr is complementary to GLP-1 therapy. Narrative shifting from headwind to tailwind.	MEDIUM

Regulatory risk assessment

Minimal / positive. FDA-cleared devices across the portfolio. CMS coverage is expanding -- net positive for DXCM as reimbursement is the enabler, not the headwind. HIPAA/data privacy requirements are manageable within existing compliance infrastructure. The regulatory environment is constructive: payer coverage is broadening, clinical guidelines (ADA) are increasingly recommending CGM for wider populations, and the FDA pathway for OTC CGM (Stelo) has been established.

Bull case

#	Factor	Detail
1	Below-Peer Valuation	Trading at a discount to med-tech peer set on a recovering CGM franchise with re-accelerating revenue and growing FCF.
2	Dense Near-Term Catalysts	T2 non-insulin coverage expansion, CMS decisions, Stelo OTC ramp, G7 15-day sensor launch. Multiple independent shots on goal.
3	Zero China Risk	Revenue is US/international diabetes care. No meaningful China exposure eliminates tariff, geopolitical, and regulatory tail risks that weigh on other med-tech names.
4	Secular Growth Theme	CGM is expanding its addressable market -- from insulin-dependent T1/T2 to non-insulin T2, pre-diabetes, and wellness. Secular tailwind, not cyclical.
5	All Financial Gates Pass	Re-accelerating revenue growth, expanding margins (15-day sensor economics), growing free cash flow. The financial profile supports the bull thesis.

Bear case

#	Factor	Severity	Detail
1	Abbott Gaining Share	HIGH	DXCM is #2 behind Abbott. FreeStyle Libre at $7.6B revenue growing 17%. Abbott launching dual-analyte (glucose + ketone) sensor. Lower price point and manufacturing scale are persistent competitive threats.
2	New CEO -- No Track Record	MEDIUM	Jake Leach is a 20-year DXCM veteran (reduces disruption risk) but unproven at CEO level. Strategic pivots or missteps under new leadership are always possible.
3	Gross Margin Compression	MEDIUM	Product transition (G6 to G7, 10-day to 15-day) creates near-term margin pressure. Ireland factory ramp adds OpEx drag in 2026 before becoming a capacity tailwind in 2027.
4	Well-Understood Bull Case	LOW-MED	The T2 expansion / Stelo / 15-day sensor thesis is consensus. Limited contrarian edge -- the catalysts are known, the question is timing and magnitude.
5	Stelo OTC Margin Dilutive	LOW-MED	OTC channel carries lower ASPs and higher customer acquisition costs near-term. Contribution margin below core Rx CGM business during ramp phase.

Score rationale

Score of 8/10 reflects a favorable risk profile where the concerns that exist are well-identified and manageable, the catalyst calendar is dense with near-term upside drivers, and structural risk factors (China, regulatory, reimbursement) are minimal or net positive.

Positives: Forward valuation sits below the med-tech peer average on a franchise with re-accelerating revenue and growing FCF (+1.5). Zero China exposure eliminates the tariff/geopolitical tail risk that weighs on most med-tech names (+1). Dense near-term catalyst slate -- T2 non-insulin, CMS, Stelo OTC, G7 15-day -- provides multiple independent shots on goal for re-rating (+1). Regulatory environment is constructive: FDA-cleared devices, CMS coverage expanding, ADA guidelines broadening CGM recommendations (+0.5). GLP-1 monitoring integration is shifting from perceived headwind to demonstrated tailwind (+0.5).

Negatives: Abbott competitive pressure is the primary overhang -- FreeStyle Libre at $7.6B revenue growing 17% with dual-analyte sensor launching. DXCM is #2 and the gap is widening in absolute terms (-1). New CEO Jake Leach is a 20-year veteran but unproven at the top level, creating a modest execution risk premium (-0.5).

Data sourced from Daloopa (company_id 6704). Analysis as of June 30, 2026.